These are interesting times for a clinician concerned about the prevention of fractures. Compared with even 10 years ago, the number of effective and Food and Drug Administration–approved treatments has increased several fold. Equally important, our ability to identify those at highest risk of fracture has improved so we can better target treatment to those most likely to benefit and avoid treatment in those who are at lower risk. The recent introduction of the fracture risk assessment tool (FRAX) is particularly noteworthy in this regard.